Journal of Clinical Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors.
38.
2020
-
Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
36:667-673.
2018
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
35:3815-3822.
2017
-
Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib.
34:871-878.
2016
-
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
33:2609-2616.
2015
-
Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600 -mutant melanoma experiencing progression with single-agent BRAF inhibitor.
32:3697-3704.
2014
-
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review.
31:3957-3963.
2013
-
BRAF inhibitor-driven tumor proliferation in akras-mutated colon carcinoma is not overcome by mek1/2 inhibition.
31:e448-e451.
2013
-
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group.
30:2654-2663.
2012
-
Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.
30:210-216.
2012
-
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
30:1505-1512.
2012
-
Reply to D.J. Stewart.
28:e651-e651.
2010
-
Randomized Phase II Trials: Inevitable or Inadvisable?.
28:2641-2647.
2010
-
Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer.
27:5965-5971.
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience..
27:e19044.
2009
-
Is It Feasible and Desirable to Collect Voluntarily Quality and Outcome Data Nationally in Palliative Oncology Care?.
26:3853-3859.
2008
-
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors.
26:3403-3410.
2008
-
Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.
24:4228-4235.
2006
-
Phase II trial of vaccination with full length NY-ESO-1/IMX in patients with advanced malignant melanoma..
24:2571.
2006
-
Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?.
23:4567-4569.
2005
-
Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study.
20:2643-2650.
2002
-
Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis.
20:9-16.
2002
-
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis.
20:9-16.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial.
19:3976-3987.
2001
-
Increased Temperature of Malignant Urinary Bladder Tumors In Vivo: The Application of a New Method Based on a Catheter Technique.
19:676-681.
2001
-
Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer.
18:2852-2861.
2000
-
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma.
18:158-158.
2000
-
Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up.
17:82-82.
1999
-
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer..
16:2181-2187.
1998
-
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor..
16:1899-1908.
1998
-
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer..
14:1787-1797.
1996
-
Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma..
13:1073-1079.
1995
-
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy..
12:1659-1666.
1994
-
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer..
12:1561-1571.
1994
-
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts..
12:1193-1203.
1994
-
Systematic review and network meta-analysis of treatment outcomes for multiple myeloma
2017
-
Dexamethasone for cancer-related fatigue
2014
-
Ketamine and Cancer Pain: The Reports of My Death Have Been Greatly Exaggerated
2013
-
A phase II study of docetaxel-carboplatin as first line therapy in the patients with visceral metastatic breast cancer: A Bangladesh experience
2006
-
Clinical experience of using docetaxel-cisplatin in the treatment of advanced ovarian cancer: A Bangladesh perspective
2006
-
Prediction of esophageal fistula from esophageal cancer CT images using multi-view multi-scale attentional convolutional neural network (MM-Atten-CNN).
2020
-
Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
2020
-
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
2020
-
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
2019
-
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.
2019
-
Arabic and Assyrian immigrants’ knowledge of hepatitis and liver cancer in Sydney, Australia. Findings of a community consultation process.
2019
-
Gene expression profiling of T-cell inflammation in small cell lung cancer.
2019
-
Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).
2019
-
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
2019
-
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
2019
-
FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.
2019
-
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
2019
-
Predictors of distress among individuals with gastric cancer.
2019
-
Valued outcomes in the cancer experience: Patient priorities and control.
2018
-
Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.
2018
-
NTRK and ALK rearrangements in mesothelioma and lung carcinoid.
2018
-
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
2018
-
Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.
2018
-
COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy.
2018
-
Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial
2018
-
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).
2017
-
P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).
2017
-
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).
2017
-
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.
2017
-
A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).
2016
-
A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.
2016
-
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
2016
-
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
2016
-
Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors.
2016
-
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.
2016
-
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
2016
-
The clinical impact of sarcopaenia on chemotherapy delivery for gastric and oesophageal cancers.
2016
-
A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
2016
-
A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.
2015
-
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
2015
-
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
2015
-
Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM)
2015
-
cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).
2015
-
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM)
2015
-
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM)
2014
-
First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.
2014
-
Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
2014
-
Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.
2014
-
Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).
2014
-
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2014
-
Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).
2014
-
Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
2014
-
Myocardial strain for detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: Results from the St. Jude lifetime cohort study.
2014
-
Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.
2014
-
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
2014
-
ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH)
2013
-
BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
2013
-
Cancer-testis antigens in triple-negative and locally advanced breast cancer.
2013
-
Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)
2013
-
Effects of angiotensin-converting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC).
2013
-
Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
2013
-
Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.
2013
-
Patterns of care of elderly patients with metastatic colorectal cancer.
2013
-
Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?
2013
-
A phase I and biodistribution study of ABT-806i, an (111)indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.
2013
-
A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).
2013
-
Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial
2012
-
Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
2012
-
Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK plus non-small cell lung cancer (NSCLC)
2012
-
Hypoxia-inducible factor 1 alpha: A screening tool for predicting development of castrate resistant prostate cancer.
2012
-
NY-ESO-1 as a predictive and prognostic marker in NSCLC
2012
-
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors
2012
-
Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort
2012
-
The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer
2012
-
11C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.
2012
-
A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC).
2011
-
Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).
2011
-
Classification of the components of the MedDietScore in relation to colorectal cancer prevalence.
2011
-
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
2011
-
Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
2011
-
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).
2011
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
-
Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer
2011
-
Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.
2010
-
Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion.
2010
-
Association of Lynch syndrome and risk of invasive cervical cancer.
2010
-
Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).
2010
-
Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up?
2010
-
Cognitive functioning pre- and postradiotherapy (RT), chemoradiotherapy (CRT), or bioradiotherapy (BRT) in patients with locally advanced squamous cell cancer of the head and neck (LA-SCCHN).
2010
-
Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.
2010
-
DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.
2010
-
Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines.
2010
-
Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors
2010
-
Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2009
-
Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study
2009
-
Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC)
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience
2009
-
A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours
2008
-
Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2008
-
Lifelong running reduces oxidative stress and degenerative changes in the testes of mice
2008
-
Phase I biodistribution study of Ley targeting immunoconjugate in advanced epithelial cancers
2008
-
Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer
2008
-
F-18-FDG PET changes management and improves prognostic stratification in patients with colorectal cancer: results of a prospective, multi-centre study
2007
-
Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
2007
-
Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with I-131-huA33
2007
-
Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).
2006
-
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides.
2005
-
A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacolkinetics, immunohistochemistry, and quantitative tumor uptake
2004
-
Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen.
2004
-
The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).
2004
-
Combination of CDK and Bcl-2 inhibitors in the treatment of soft-tissue sarcomas
2018
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)